Triglyceride otic formulations and uses thereof

Abstract

Disclosed herein are triglyceride based formulations, compositions, and methods for the treatment of otic diseases and conditions. Such triglyceride based formulations and compositions are derived from medium chain triglycerides and allow for the delivery of a variety of therapeutic agents to the outer, middle, and/or inner ear.

What is claimed is: 
     
         1 . An otic pharmaceutical formulation comprising:
 a) a therapeutic agent, or pharmaceutically acceptable prodrug or salt thereof; and   b) triglycerides comprising medium chain fatty acids;   
       wherein the triglycerides are present in an amount that is sufficient to stabilize the therapeutic agent for injection into the ear, and wherein the otic pharmaceutical formulation comprises at least about 50% by weight of the triglycerides. 
     
     
         2 . The otic pharmaceutical formulation of  claim 1 , wherein the triglycerides are present in an amount that is sufficient to provide sufficient retention time in the ear. 
     
     
         3 . The otic pharmaceutical formulation of  claim 1 , wherein the triglycerides are present in an amount that is sufficient to provide sustained release of the therapeutic agent. 
     
     
         4 . The otic pharmaceutical formulation of  claim 1 , wherein the triglycerides are present in an amount that is sufficient to allow delivery of the formulation via a narrow gauge needle. 
     
     
         5 . The otic pharmaceutical formulation of  claim 1 , wherein the triglycerides are derived from glycerol and medium chain fatty acids. 
     
     
         6 . The otic pharmaceutical formulation of  claim 5 , wherein the medium chain fatty acids are caproic acid (hexanoic acid), enanthic acid (heptanoic acid), caprylic acid (octanoic acid), pelargonic acid (nonanoic acid), capric acid (decanoic acid), undecylenic acid (undec-10-enoic acid), lauric acid (dodecanoic acid), or a combination thereof. 
     
     
         7 . The otic pharmaceutical formulation of  claim 1 , wherein the otic pharmaceutical formulation comprises between about 50% to about 99.99% by weight of the triglycerides. 
     
     
         8 . The otic pharmaceutical formulation of  claim 1 , wherein the otic pharmaceutical formulation further comprises at least one viscosity modulating agent. 
     
     
         9 . The otic pharmaceutical formulation of  claim 8 , wherein the at least one viscosity modulating agent is silicon dioxide, povidone, carbomer, poloxamer, or a combination thereof. 
     
     
         10 . The otic pharmaceutical formulation of  claim 9 , wherein the viscosity modulating agent is silicon dioxide. 
     
     
         11 . The otic pharmaceutical formulation of  claim 9 , wherein the viscosity modulating agents are silicon dioxide and povidone. 
     
     
         12 . The otic pharmaceutical formulation of  claim 11 , wherein the otic pharmaceutical formulation comprises between about 0.01% to about 20% by weight of the povidone. 
     
     
         13 . The otic pharmaceutical formulation of  claim 9 , wherein the viscosity modulating agents are silicon dioxide and carbomer. 
     
     
         14 . The otic pharmaceutical formulation of  claim 13 , wherein the otic pharmaceutical formulation comprises between about 0.01% to about 20% by weight of the carbomer. 
     
     
         15 . The otic pharmaceutical formulation of  claim 9 , wherein the viscosity modulating agents are silicon dioxide and poloxamer. 
     
     
         16 . The otic pharmaceutical formulation of  claim 15 , wherein the otic pharmaceutical formulation comprises between about 0.01% to about 20% by weight of the poloxamer. 
     
     
         17 . The otic pharmaceutical formulation of  claim 9 , wherein the otic pharmaceutical formulation comprises between about 0.01% to about 10% by weight of the silicon dioxide. 
     
     
         18 . The otic pharmaceutical formulation of  claim 1 , wherein the otic pharmaceutical formulation has a viscosity between about 10 cP to about 10,000 cP. 
     
     
         19 . The otic pharmaceutical formulation of  claim 1 , wherein the therapeutic agent is an immunomodulating agent, an aural pressure modulating agent, a corticosteroid, an antimicrobial agent, an otic neurotrophic factor, an antagonist of truncated TrkC or truncated TrkB, a non-natural TrkB or Trk C agonist, or a WNT modulator. 
     
     
         20 . The otic pharmaceutical formulation of  claim 19 , wherein the therapeutic agent is dexamethasone, ciprofloxacin, or gacyclidine. 
     
     
         21 . The otic pharmaceutical formulation of  claim 19 , wherein the otic neurotrophic factor is selected from brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), glial cell-line derived neurotrophic factor (GDNF), neurotrophin-3, neurotrophin-4, fibroblast growth factor (FGF), insulin-like growth factor (IGF), epidermal growth factor (EGF), platlet-derived growth factor (PGF), and combination thereof. 
     
     
         22 . The otic pharmaceutical formulation of  claim 21 , wherein the otic neurotrophic factor is selected from brain-derived neurotrophic factor (BDNF), neurotrophin-3, and combination thereof. 
     
     
         23 . The otic pharmaceutical formulation of  claim 1 , wherein the otic pharmaceutical formulation comprises between about 0.01% to about 20% by weight of the therapeutic agent, or pharmaceutically acceptable prodrug or salt thereof. 
     
     
         24 . The otic pharmaceutical formulation of  claim 1 , wherein the retention time of the formulation in the ear is at least 1 day. 
     
     
         25 . The otic pharmaceutical formulation of  claim 1 , wherein the therapeutic agent is released from the formulation for a period of at least 1 day. 
     
     
         26 . The otic pharmaceutical formulation of  claim 1 , wherein the otic pharmaceutical formulation is free or substantially free of water, C1-C6 alcohols or C1-C6 glycols, C1-C4 alcohols or C1-C4 glycols, or any combination thereof. 
     
     
         27 . The otic pharmaceutical formulation of  claim 1 , further comprising a drug delivery device selected from a needle and syringe, a pump, a microinjection device, a wick, a spongy material and combinations thereof. 
     
     
         28 . The otic pharmaceutical formulation of  claim 1  for use in the treatment of an otic disease or condition associated with the outer, middle, and/or inner ear. 
     
     
         29 . The otic pharmaceutical formulation of  claim 28 , wherein the otic disease or condition is ceruminosis or ceruminosis associated with an otic disease or condition, ear pruritus, otitis externa, otalgia, tinnitus, vertigo, ear fullness, hearing loss, Meniere's disease, sensorineural hearing loss, noise induced hearing loss, age related hearing loss (presbycusis), auto immune ear disease, tinnitus, ototoxicity, excitotoxicity, endolymphatic hydrops, labyrinthitis, Ramsay Hunt's Syndrome, vestibular neuronitis, or microvascular compression syndrome, hyperacusis, presbystasis, central auditory processing disorder, auditory neuropathy, improvement of cochlea implant performance, or a combination thereof. 
     
     
         30 . A method of treating an otic disease or condition in a subject in need thereof, the method comprising administering to the subject the otic pharmaceutical formulation of  claim 1 .